ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ao Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7205-9202; OpenAlex author ID A5100437584. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine derivatives as p21-activated kinase 4 inhibitors for treatment o… Last author DOI 10.1016/j.apsb.2024.10.002 ↗
Hsp90α promotes chemoresistance in pancreatic cancer by regulating Keap1-Nrf2 axis and inhibiting ferroptosis. Co-author DOI 10.3724/abbs.2024138 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yang Li · 1 shared paper, 2025 · strength 0.25
- Paper Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine derivatives as p21-activ… DOI 10.1016/j.apsb.2024.10.002 ↗
Daohai Qian · 1 shared paper, 2024 · strength 0.21
- Paper Hsp90α promotes chemoresistance in pancreatic cancer by regulating Keap1-Nrf2 axis and inhibiting ferroptosis. DOI 10.3724/abbs.2024138 ↗
Bin Liu · 1 shared paper, 2024 · strength 0.21
- Paper Hsp90α promotes chemoresistance in pancreatic cancer by regulating Keap1-Nrf2 axis and inhibiting ferroptosis. DOI 10.3724/abbs.2024138 ↗
Xiaoming Wang · 1 shared paper, 2024 · strength 0.21
- Paper Hsp90α promotes chemoresistance in pancreatic cancer by regulating Keap1-Nrf2 axis and inhibiting ferroptosis. DOI 10.3724/abbs.2024138 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.